vaccine for coronavirus

Trial of a new ‘Sanofi’ vaccine for coronavirus started in Jaipur

Trial of 'Sanofi' drug made by French pharma company on 500 volunteers; Second dose will be administered after 21 days


The trial of the third phase of the vaccine for Covid made by French pharma company ‘Sanofi’ and UK’s pharma company GSK is going on at a private hospital in Vidya Nagar, Jaipur. 500 people will take the first dose. The second dose will be provided after a gap of 21 days. This trial is being done on people aged 18 and above. 

According to the Principal Investigator (PI) of the clinical trial, “The company has asked 500 people to perform the trial and each of them is provided with a dose of 0.5ml. This year, people are less fearful than last year about the trial. A large number of people are participating in it.”

“Earlier trials of the second phase of ZyCov-D made by Zydus Cadila Company and the third phase of Bharat Biotech’s Covaxin were performed in Jaipur. Though Johnson & Johnson and Moderna have also got the approval, they are yet unavailable in India. Apart from this, a few days ago, Zydus Cadila’s Zykov-D was approved by DGCI for emergency use. Presently, Serum Institute’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik-V are being used in India,” he added. 

Continuous Monitoring will be done

He further said that the volunteers who are being given doses are being continuously monitored. They are contacted by telephone. However, volunteers have been told earlier that there may be mild fever or slight complaints of pain at the site of the vaccine. Still, if there is any problem, then our team is ready for that. The second dose will be administered after a gap of 21 days.

There have been 2 trials yet

Till now, the company has performed two-phase trials of this vaccine in other countries outside India. The trials of the first phase have positive outcomes. This vaccine has proved to be effective on the South Africa variant in the trials conducted abroad.

Notify of
Inline Feedbacks
View all comments